Company Profile
UCB SA, a biopharmaceutical company develops products and solutions for people with neurology and immunology diseases globally. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis.
Its portfolio also includes Vimpat, Keppra, and Briviact for epilepsy, and Neupro for Parkinson's disease and restless legs syndrome, as well as Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters Zyrtec and Xyzal for allergies. Additionally, it offers Evenity for the treatment of osteoporosis in postmenopausal women.
Its portfolio also includes Bimzelx to treat plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis, Fintepla for the treatment of Dravet and Lennox-Gastaut syndrome, and RYSTIGGO and ZILBRYSQ to treat people living with generalized myasthenia gravis. It also develops KYGEVVI (doxecitine/doxribtimine) for thymidine kinase 2 deficiency disorder.
Its portfolio also includes fenfluramine to treat CDKL5 deficiency disorder, and RETT-Syndrome, dapirolizumab pegol for systemic lupus erythematosus, STACCATO alprazolam for treating stereotypical prolonged seizures, bepranemab to treat Alzheimer's disease, and UCB9741 for atopic dermatitis, non cystic fibrosis bronchiectasis, and chronic obstructive pulmonary disease. Additionally, it engages in the contract manufacturing activities. Incorporated in 1925, the company is headquartered in Brussels, Belgium.